Size Matters to Industry

Large molecules are more likely to make it to market these days than small molecules, according to new reports.

By | April 11, 2012

image: Size Matters to Industry Flickr, Steve Snodgrass


A number of recent reports are highlighting the fact that the pharmaceutical industry is solidly moving in favor of the large molecule drugs known as biologics.  Although they are more difficult to make than small molecule compounds, they are also more difficult to reproduce generically, which may give companies a longer market advantage than for small molecule drugs.

Companies are making biologics a bigger part of their drug portfolios, with patent filings for this class of drugs increasing even while the overall patent numbers have gone down in recent years, according to a recent report by the law firm Withers & Rogers.  Another study by the biopharma consultancy company KMR Group showed that large molecule drugs also have a better chance of winning approval from the US Food and Drug Administration than small molecule products.

Why are small molecules getting short shrift? “It may be that large molecule development, in general, is more targeted ,” Joseph DiMasi, director of economic analysis for Tufts Center for the Study of Drug Development, told Genetic Engineering & Biotechnology News. As a result, he said, their “safety issues may be less prevalent.”


Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Inside a Lab Mouse’s High-Fat Diet
  2. Antidepressant Exerts Epigenetic Changes
  3. How Gastric Bypass Can Kill Sugar Cravings
  4. Birth of the Skin Microbiome
    Daily News Birth of the Skin Microbiome

    The immune system tolerates the colonization of commensal bacteria on the skin with the aid of regulatory T cells during the first few weeks of life, a mouse study shows.

Life Technologies